Intellia Therapeutics (NASDAQ:NTLA) Receives Buy Rating from Chardan Capital

Chardan Capital reiterated their buy rating on shares of Intellia Therapeutics (NASDAQ:NTLA) in a research report sent to investors on Friday morning,Benzinga reports. Chardan Capital currently has a $68.00 target price on the stock.

A number of other research firms have also weighed in on NTLA. Morgan Stanley lowered shares of Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and reduced their target price for the stock from $56.00 to $11.00 in a report on Monday, January 27th. Citigroup increased their price objective on Intellia Therapeutics from $12.00 to $14.00 and gave the company a “neutral” rating in a report on Friday, February 28th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $13.00 target price (down from $45.00) on shares of Intellia Therapeutics in a report on Friday, February 28th. Oppenheimer decreased their price target on Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating for the company in a research note on Monday, January 13th. Finally, Wells Fargo & Company cut their price objective on Intellia Therapeutics from $60.00 to $50.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. Two research analysts have rated the stock with a sell rating, six have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $36.47.

Intellia Therapeutics Stock Performance

Shares of NTLA opened at $8.12 on Friday. Intellia Therapeutics has a 52 week low of $5.90 and a 52 week high of $28.18. The stock has a market capitalization of $841.09 million, a price-to-earnings ratio of -1.49 and a beta of 2.33. The stock has a fifty day moving average of $8.13 and a 200-day moving average of $11.06.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, May 8th. The company reported ($1.10) EPS for the quarter, beating the consensus estimate of ($1.26) by $0.16. The firm had revenue of $16.63 million during the quarter, compared to the consensus estimate of $11.39 million. Intellia Therapeutics’s revenue for the quarter was down 42.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.12) earnings per share. As a group, equities analysts forecast that Intellia Therapeutics will post -5.07 EPS for the current year.

Institutional Investors Weigh In On Intellia Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. GF Fund Management CO. LTD. bought a new position in shares of Intellia Therapeutics in the fourth quarter valued at approximately $25,000. Sterling Capital Management LLC raised its position in Intellia Therapeutics by 866.2% in the 4th quarter. Sterling Capital Management LLC now owns 3,198 shares of the company’s stock valued at $37,000 after buying an additional 2,867 shares during the last quarter. Harbour Investments Inc. lifted its stake in Intellia Therapeutics by 76.7% during the 1st quarter. Harbour Investments Inc. now owns 5,214 shares of the company’s stock valued at $37,000 after acquiring an additional 2,264 shares in the last quarter. Whipplewood Advisors LLC purchased a new position in Intellia Therapeutics during the 4th quarter worth $40,000. Finally, Resona Asset Management Co. Ltd. bought a new stake in shares of Intellia Therapeutics in the 4th quarter worth $43,000. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.